B‐lineage antigens that are useful to substitute CD19 for minimal residual disease monitoring in B cell precursor acute lymphoblastic leukemia after CD19 targeting. Issue 5 (7th July 2022)

• Record Type: Journal Article
• Authors: Mikhailova, Ekaterina; Itov, Albert; Zerkalenkova, Elena; Roumiantseva, Julia; Olshanskaya, Yulia; Karachunskiy, Alexander; Novichkova, Galina; Maschan, Michael; Popov, Alexander
• Is Part Of: Cytometry. Volume 102:Issue 5(2022)
• Page Start: 353
• Page End: 359
• Publication Date: 2022-07-07
• Subjects: CD19 loss -- CD19 targeting -- flow cytometry -- minimal residual disease; Flow cytometry -- Diagnostic use -- Periodicals; Cytodiagnosis -- Periodicals; 616.07582
• DOI: 10.1002/cyto.b.22088
• Languages: English
• ISSNs: 1552-4949

Abstract

Abstract: Background: The potential loss of CD19 during targeted treatment of B cell precursor acute lymphoblastic leukemia (BCP‐ALL) can hamper flow cytometric minimal residual disease (MRD) monitoring. In the current study, we present expression data for antigens that are candidates for CD19 substitution: surface CD22, CD24, CD10, and intracellular (i) CD79a. Methods: Bone marrow samples from 519 consecutive children (below 18 y.o.) with primary BCP‐ALL were studied with a focus on expression of CD19, CD10, CD22, CD24, and iCD79a. As these antigens are planned to be used as substitutions for CD19 for primary B cell gating, only total expression on the leukemic population (≥95% cells) was considered appropriate. Results: It was found that each of these antigens is totally expressed in nearly 90% of patients. For each single marker, a subgroup of patients without complete positivity presented with BCP‐ALL harboring diverse cytogenetic and molecular genetic aberrations. Based on expression data, we have developed algorithm of simultaneous application of these antigens for initial B‐lineage compartment gating, that is applicable for nearly all patients after CD19 targeting. Conclusion: We conclude that the addition of CD22, CD24, and iCD79a to the conventional antibody panel and their application together with CD10 allow for the identification of B‐lineage compartment including residual tumor blasts, for MFC‐MRD searching in virtually all patients with BCP‐ALL after CD19‐directed treatment.